These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
314 related items for PubMed ID: 23083525
1. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP, Cooper WO. Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525 [Abstract] [Full Text] [Related]
4. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Jick SS, Kaye JA, Russmann S, Jick H. Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485 [Abstract] [Full Text] [Related]
5. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476 [Abstract] [Full Text] [Related]
6. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. Dinger J, Assmann A, Möhner S, Minh TD. J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364 [Abstract] [Full Text] [Related]
7. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Cole JA, Norman H, Doherty M, Walker AM. Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834 [Abstract] [Full Text] [Related]
10. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. Raymond EG, Burke AE, Espey E. Obstet Gynecol; 2012 May; 119(5):1039-44. PubMed ID: 22525916 [Abstract] [Full Text] [Related]
11. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Dinger J, Bardenheuer K, Heinemann K. Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793 [Abstract] [Full Text] [Related]
12. [Venous thromboembolism in adolescents associated with fourth-generation oral contraceptives]. Botzenhardt S, Toni I, Rascher W, Neubert A. Klin Padiatr; 2013 Sep; 225(5):268-76. PubMed ID: 23979828 [Abstract] [Full Text] [Related]
13. Another flawed database study. Szarewski A, Mansour D, Shapiro S. Contraception; 2013 Apr; 87(4):505-6. PubMed ID: 23261232 [No Abstract] [Full Text] [Related]
18. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Sehovic N, Smith KP. Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756 [Abstract] [Full Text] [Related]
19. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604 [Abstract] [Full Text] [Related]
20. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Jick SS, Jick H. Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227 [Abstract] [Full Text] [Related] Page: [Next] [New Search]